Discovery Labs Wins Approval for Drug to Ease Baby Breathing
This article is for subscribers only.
Discovery Laboratories Inc. won approval for its treatment to prevent respiratory distress in high-risk premature infants on its fifth try to get the drug on the market. The shares gained in late trading.
The Food and Drug Administration cleared the Warrington, Pennsylvania-based company’s leading product, Discovery Laboratories said in a statement today. The company said it expects the drug, Surfaxin, will be commercially available in the U.S. in late 2012.